N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of C-proteinase and for treating or preventing disorders related to unregulated collagen production

Abstract

The present invention relates to a novel class of organic molecules capable of inhibiting C-proteinase, and to their use to regulate, modulate and/or inhibit abnormal collagen formation as a therapeutic approach towards the treatment of fibrotic disorders.

What is claimed:  
     
         1 . A compound having an inhibitory effect on C-proteinase and having the structural formula:  
       
         
           
           
               
               
           
         
         or pharmaceutically acceptable salts thereof, wherein: 
 a is an integer from 1 to 4;  
 b is an integer from 0 to 4;  
 c is an integer from 0 to 4;  
 Ar 1  is selected from the group consisting of (C 5 -C 20 ) aryl, (C 5 -C 20 ) aryl independently substituted with one or more Y 1 , 5-20 membered heteroaryl, and 5-20 membered heteroaryl independently substituted with one or more Y 1 ;  
 Ar 2  is selected from the group consisting of (C 5 -C 20 ) aryl, (C 5 -C 20 ) aryl independently substituted with one or more Y 2 , 5-20 membered heteroaryl, and 5-20 membered heteroaryl independently substituted with one or more Y 2 ;  
 each Y 1  is independently selected from the group consisting of an electron-donating functional group, an electron-withdrawing functional group, and a lipophilic functional group; and  
 each Y 2  is independently selected from the group consisting of a functional group having an acidic hydrogen, a functional group capable of participating in a hydrogen bond, a polar functional group, an electron-withdrawing functional group, an electron-donating functional group, and a lipophilic functional group,  
 with the provisos that 
 (i) when a and b are each one, c is zero and Ar 2  is 4′-methoxyphenyl, then Ar 1  is other than phenyl, 4′-fluorophenyl, 4′-chlorophenyl, 4′-trifluoromethylphenyl or 4′-methoxyphenyl;  
 (ii) when a and b are each one, c is zero and Ar 2  is phenyl, then Ar 1  is other than 4′-chlorophenyl;  
 (iii) when a is two, b and c are each zero and Ar 1  is phenyl, then Ar 2  is other than 4′-chlorophenyl or 4′-bromophenyl; and  
 (iv) when a and b are each one, c is zero and Ar 2  is phenyl, then Ar 1  is other than carbocyclic aryl-lower alkyl, carbocyclic aryl, heterocyclic aryl, biaryl, biaryl-lower alkyl, heterocyclic aryl-lower alkyl, or (N-aryl-lower alkylpiperazino)-lower alkyl,  
 wherein, in proviso (iv), aryl represents monocyclic or bicyclic aryl, carbocyclic aryl represents monocyclic or bicyclic carbocyclic aryl and heterocyclic aryl represents monocyclic or bicyclic heterocyclic aryl.  
 
 
       
     
     
         2 . The compound of  claim 1  wherein Y 1  and Y 2  are each independently selected from the group consisting of halogen, —R, —OR, —SR, —NRR, —NO, —NO 2 , —CN, -trihalomethyl, and —SO 2 NH 2 ; where each R is independently selected from the group consisting of H, (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, and (C 2 -C 8 ) alkynyl.  
     
     
         3 . The compound of  claim 1  wherein each Y 2  is independently selected from the group consisting of -halogen, -trihalomethyl, —R, —C(O)OR, —CN, —C(O)—NR—OR, —C(NRR)═N—OR, —C(O)—R, —C(O)NRR, —C(S)NRR, —C(NHR)═NR, —NRR, —NO 2 , —NH—C(O)R, —NH—C(O)—NRR, —NH—C(O)—OR, —NH—SO 2 —R, —NH—C(S)—NRR, ,—NH—C(O)R, —NR—C(O)—NRR, —NR—C(S)—NRR, —OR, —P(O)(OH)(NRR), —P(O)(OH) 2 , —SO 2 R, —S(O)—R, —SO 3 H, —SR, and -tetrazole; where each R is independently selected from the group consisting of H,(C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, (C 5 -C 20 ) aryl, (C 6 -C 25 ) alkaryl, 5-20 membered heteroaryl and 6-26 membered alk-heteroaryl.  
     
     
         4 . The compound of  claim 1  wherein Ar 1  is selected from the group consisting of (C 5 -C 20 ) aryl and (C 5 -C 20 ) aryl independently substituted with one or more Y 1 ; and Ar 2  is selected from the group consisting of (C 5 -C 20 ) aryl and (C 5 -C 20 ) aryl independently substituted with one or more Y 2 .  
     
     
         5 . The compound of  claim 4  having the structural formula:  
       
         
           
           
               
               
           
         
         or pharmaceutically acceptable salts thereof, wherein 
 a, b, and c are as defined in  claim 1;   
 R 1 , R 2 , R 3 , R 4  and R 5  are each independently selected from the group consisting of H, an electron-donating functional group, an electron-withdrawing functional group, and a lipophilic functional group;  
 R 6 , R 7 , R 8 , R 9  and R 10  are each independently selected from the group consisting of H, a functional group having an acidic hydrogen, a functional group capable of participating in a hydrogen bond, a polar functional group, an electron-withdrawing functional group, an electron-donating functional group, and a lipophilic functional group;  
 with the provisos that 
 (i) when a and b are each one then c is other than zero; and  
 (ii) when a is two, b and c are each zero and R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , R 9  and R 10  are each —H, then R 8  is other than —F or —Cl.  
 
 
       
     
     
         6 . The compound of  claim 5  wherein R 1 , R 2 , R 3 , R 4  and R 5  are each independently selected from the group consisting of —R, halogen, —OR, —SR, —NRR, —COOH, —SO 3 H, —P(O)(OH) 2 , —C(O)—NH—OH, —P(O)(OH)(NRR), and tetrazole; where each R is independently selected from the group consisting of H, (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl and (C 2 -C 8 ) alkynyl.  
     
     
         7 . The compound of  claim 5  wherein R 6 , R 7 , R 8 , R 9  and R 10 ) are each independently selected from the group consisting of —H, —C(NHR)═N—OH, —NH—C(O)R, —NH—C(O)—NRR, —C(S)NHR, —C(O)NHR, —CO 2 H, —NR 2 , —C(NHR)═NR, —NH—(CO)—OR, —NH—SO 2 —R, —C≡N, —OR, —SR, —SO 2 R, —S(O)R, —NO 2 , and trihalomethyl; where each R is independently selected from the group consisting of H, (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl and (C 2 -C 8 ) alkynyl.  
     
     
         8 . The compound of  claim 5  wherein: 
 a is an integer from 2 to 4;  
 b is an integer from 0 to 4; and  
 c is zero.  
 
     
     
         9 . The compound of  claim 8  wherein: 
 a is an integer from 2 to 3;  
 b is an integer from 0 to 2;  
 R 3  and R 4  are each independently selected from the group consisting of —H, halogen, —OR, and trihalomethyl;  
 R 5  is selected from the group consisting of —H and —OR;  
 R 6  is selected from the group consisting of —H, —C(O)OR, —C(NH 2 )═NOH and —SO 2 R;  
 R 7  is selected from the group consisting of —H and —C(NH 2 )═NOH;  
 R 8  is selected from the group consisting of —H, —OR, —NO 2 , —C(O)OR, —SO 2 R and —C(NH 2 )═NOH; and  
 each R is independently selected from the group consisting of H, (C 1 -C 3 ) alkyl, (C 2 -C 3 ) alkenyl, and (C 2 -C 3 ) alkynyl.  
 
     
     
         10 . The compound of  claim 5  selected from the group consisting of FG 121, FG 122, FG 123, FG 124, FG 125, FG 126, FG 128, FG 134, FG 202, FG 204, FG 206, FG 208, FG 1268, FG 1300, FG 1301, FG 1405, FG 1455, FG 1456, FG 1459, FG 1460, FG 1465, FG 1468 and FG 1474.  
     
     
         11 . The compound of  claim 1  having the structural formula:  
       
         
           
           
               
               
           
         
         or pharmaceutically acceptable salts thereof, wherein a, b, c, Ar 2 , and Y 2  are as defined in  claim 1  with the proviso that when a and b are 1 and Ar 2  is phenyl, then c is other than 0.  
       
     
     
         12 . The compound of  claim 11  wherein Y 2  is selected from the group consisting of -halogen, -trihalomethyl, —R, —C(O)OR, —CN, —C(O)—NR—OR, —C(NRR)═N—OR, —C(O)—R, —C(O)NRR, —C(S)NRR, —C(NHR)═NR, —NRR, —NO 2 , —NH—C(O)R, —NH—C(O)—NRR, —NH—C(O)—OR, —NH—SO 2 —R, —NH—C(S)—NRR, ,—NH—C(O)R, —NR—C(O)—NRR, —NR—C(S)—NRR, —OR, —P(O)(OH)(NRR), —P(O)(OH) 2 , —SO 2 R, —S(O)—R, —SO 3 H, —SR, and -tetrazole; where each R is independently selected from the group consisting of H, (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, (C 5 -C 20 ) aryl, (C 6 -C 26 ) alkaryl, 5-20 membered heteroaryl and 6-26 membered alk-heteroaryl.  
     
     
         13 . The compound of  claim 1  wherein Ar 2  is selected from the group consisting of phenyl, phenyl mono-substituted with Y 2 , thienyl, and thienyl mono-substituted with Y 2 .  
     
     
         14 . The compound of  claim 11  wherein Ar 2  is selected from the group consisting of phenyl, phenyl mono-substituted with Y 2  , thienyl, and thienyl mono-substituted with Y 2 .  
     
     
         15 . The compound of  claim 11  that is selected from the group consisting of FG 202, FG 204, FG 206, FG 208, FG 1455, FG 1456, FG 1459, FG 1460, FG 1465, FG 1468, FG 1471, and FG 1489.  
     
     
         16 . The compound of  claim 1  wherein Ar 2  is phenyl substituted with one or more Y 2  with the proviso that when a and b are 1 then c is other than 0.  
     
     
         17 . The compound of  claim 16  wherein Y 2  are each independently selected from the group consisting of —R, —OR, —SR, —NRR, —NO 2 , —CN, halogen, trihalomethyl, —C(O)R, —C(O)OR, —C(O)NRR, —C(NRR)═NOR, —NR—C(O)R, —NR—C(O)—NRR, —NR—C(O)—OR, tetrazol-5-yl, —NR—SO 2 —R, and —SO 2 R; where each R is independently selected from the group consisting of H, (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, and (C 2 -C 8 ) alkynyl.  
     
     
         18 . The compound of  claim 16  having the structural formula:  
       
         
           
           
               
               
           
         
         and pharmaceutically acceptable salts thereof, wherein R 125 , R 126  and R 127  are each independently selected from the group consisting of —H, —OR, —C(O)R, —C(O)OR, —C(O)NRR, —C(NH 2 )NOH, —NH—C(O)R, —NR—C(O)—NRR, —NR—C(O)—OR, —NR—SO 2 —R, -tetrazol-5-yl and —SO 2 R; and each R is independently selected from the group consisting of hydrogen, (C 1 -C 6 ) alkyl, (C 2 -C 6 ) alkenyl and (C 2 -C 6 ) alkynyl, with the proviso that when a is 1 then b is other than 1.  
       
     
     
         19 . The compound of  claim 18  wherein Ar 1  is selected from the group consisting of phenyl, pyridinyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl, and thienyl.  
     
     
         20 . The compound of  claim 18  that is selected from the group consisting of FG 1132, FG 1374, FG 1273, FG 1357, FG 1372, FG 1410, FG 1464, FG 1369, FG 1458, FG 1414, FG 1416, FG 1411, FG 1463, FG 1457, FG 1409, FG 121, FG 122, FG 123, FG 124, FG 125, FG 126, FG 128, FG 134, FG 202, FG 204, FG 206, FG 208, FG 1300, FG 1405, FG 1455, FG 1456, FG 1460, FG 1268, FG 1459, FG 1465 and FG 1468.  
     
     
         21 . The compound of  claim 1  wherein 
 each Y 1  is independently selected from the group consisting of —SO 2 NH 2 , —R′, —OR′, —SR′, —NR′R′, —NO 2 , —CN, -halogen and trihalomethyl;  
 each Y 2  is independently selected from the group consisting of —R′, —OR′, —OR″, —SR′, —SR″, —NR′R′, —NO 2 , —CN, -halogen, -trihalomethyl, trihalomethoxy, —C(O)R′, —C(O)OR′, —C(O)NR′R′, —C(O)NR′OR′, —C(NR′R′)═NOR′, —NR′—C(O)R′, —SO 2 R′, —SO 2 R″, —NR′—SO 2 —R′, —NR′—C(O)—NR′R′, -tetrazol-5-yl, —NR′—C(O)—OR′, —C(NR′R′)═NR′, —S(O)—R′, —S(O)—R″, and —NR′—C(S)—NR′R′;  
 each R′ is independently selected from the group consisting of H, (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl and (C 2 -C 8 ) alkynyl;  
 each R″ is independently selected from the group consisting of (C 5 -C 20 ) aryl and (C 5 -C 20 ) aryl independently substituted with one or more —OR′, —SR′, —NR′R′, —NO 2 , —CN, halogen or trihalomethyl groups.  
 
     
     
         22 . The compound of  claim 1  wherein Ar 1  is thienyl with the proviso that when a and b are each one and Ar 2  is phenyl then c is other than zero.  
     
     
         23 . The compound of  claim 22  wherein 
 each Y 2  is independently selected from the group consisting of —R′, —OR′, —OR″, —SR′, —SR″, —NR′R′, —NO 2 , —CN, -halogen, -trihalomethyl, trihalomethoxy, —C(O)R′, —C(O)OR′, —C(O)NR′R′, —C(O)NR′OR′, —C(NR′R′)═NOR′, —NR′—C(O)R′, —SO 2 R′, —SO 2 R″, —NR′—SO 2 —R′, —NR′—C(O)—NR′R′, tetrazol-5-yl, —NR′—C(O)—OR′, —C(NR′R′)═NR′, —S(O)—R′, —S(O)—R″, and —NR′—C(S)—NR′R′;  
 each R′ is independently selected from the group consisting of —H, (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl and (C 2 -C 8 ) alkynyl; and  
 each R″ is independently selected from the group consisting of (C 5 -C 20 ) aryl and (C 5 -C 20 ) aryl independently substituted with one or more —OR′, —SR′, —NR′R′, —NO 2 , —CN, halogen or trihalomethyl groups.  
 
     
     
         24 . The compound of  claim 22  wherein Ar 1  is thien-2-yl.  
     
     
         25 . The compound of  claim 24  that is selected from the group consisting of FG 1417, FG 1419, FG 1420, FG 1421, FG 1423, FG 1425 and FG 1472.  
     
     
         26 . The compound of  claim 22  wherein: 
 Ar 2  is selected from the group consisting of phenyl, phenyl independently mono- or di-substituted with Y 2 , 5-10 membered heteroaryl, and 5-10 membered heteroaryl independently mono- or di-substituted with Y 2 ;  
 each Y 2  is independently selected from the group consisting of —R′, —OR′, —OR″, —SR′, —SR″, —NR′R′, —NO 2 , —CN, -halogen, -trihalomethyl, trihalomethoxy, —C(O)R′, —C(O)OR′, —C(O)NR′R′, —C(O)NR′OR′, —C(NR′R′)═NOR′, —NR′—C(O)R′, —SO 2 R′, —SO 2 R″, —NR′—SO 2 —R′, —NR′—C(O)—NR′R′, tetrazol-5-yl, —NR′—C(O)—OR′, —C(NR′R′)═NR′, —S(O)—R′, —S(O)—R″, and —NR′—C(S)—NR′R′;  
 each R′ is independently selected from the group consisting of —H, (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl and (C 2 -C 8 ) alkynyl; and  
 each R″ is independently selected from the group consisting of phenyl and phenyl independently mono- or di-substituted with halogen, —NR′R′, —NO 2  or —CN,  
 with the proviso that when a and b are each one and Ar 2  is phenyl then c is other than zero.  
 
     
     
         27 . The compound of  claim 22  wherein Ar 2  is selected from the group consisting of thienyl, 2,1,3-benzothiadiazolyl, imidazolyl, 1,7-thiazopyrrolizinyl, phenyl, and phenyl independently mono-, di- or tri-substituted with Y 2 .  
     
     
         28 . The compound of  claim 22  having the structural formula:  
       
         
           
           
               
               
           
         
         wherein R 118 , R 119  and R 120  are each independently selected from the group consisting of —R′, —OR′, —OR″, —SR′, —SR″, —NR′R′, —NO 2 , —CN, -halogen, -trihalomethyl, trihalomethoxy, —C(O)R′, —C(O)OR′, —C(O)NR′R′, —C(O)NR′OR′, —C(NR′R′)═NOR′, —NR′—C(O)R′, —SO 2 R′, —SO 2 R″, —NR′—SO 2 —R′, —NR′—C(O)—NR′R′, tetrazol-5-yl, and —NR′—C(O)—OR′;  
         each R′ is independently selected from the group consisting of —H, (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl and (C 2 -C 8 ) alkynyl; and  
         R″ is independently selected from the group consisting of phenyl and phenyl independently mono-, di-substituted or tri-substituted with halogen or —CN, with the proviso that when a and b are each one then c is other than zero.  
       
     
     
         29 . The compound of  claim 28  selected from the group consisting of FG 1302, FG 1407, FG 1408, FG 1409, FG 1411, FG 1414, FG 1415, FG 1416, FG 1418, FG 1422, FG 1424, FG 1457, FG 1461, FG 1463, FG 1466 and FG 1469.  
     
     
         30 . The compound of  claim 28  wherein a is two, b is two and c is zero.  
     
     
         31 . The compound of  claim 22  wherein Ar 2  is thienyl or thienyl independently substituted with one or more Y 2 .  
     
     
         32 . The compound of  claim 31  having the structural formula:  
       
         
           
           
               
               
           
         
         or pharmaceutically acceptable salts thereof, wherein:  
         R 121  is selected from the group consisting of —R′, —OR′, —OR″, —SR′, —SR″, —NR′R′, —NO 2 , —CN, -halogen, -trihalomethyl, trihalomethoxy, —C(O)R′, —C(O)OR′, —C(O)NR′R′, —C(O)NR′OR′, —C(NR′R′)═NOR′, —NR′—C(O)R′, —SO 2 R′, —SO 2 R″, —NR′—SO 2 —R′, —NR′—C(O)—NR′R′, tetrazol-5-yl, and —NR′—C(O)—OR′; 
 R′ is selected from the group consisting of —H, (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl and (C 2 -C 8 ) alkynyl; and  
 R″ is (C 5 -C 10 ) aryl.  
 
       
     
     
         33 . The compound of  claim 32  selected from the group consisting of FG 1417, FG 1419, FG 1425, and FG 1472.  
     
     
         34 . The compound of  claim 31  wherein a is two, b is two and c is zero.  
     
     
         35 . The compound of  claim 1  having the structural formula:  
       
         
           
           
               
               
           
         
         or pharmaceutically acceptable salts thereof.  
       
     
     
         36 . The compound of  claim 35  wherein: 
 Ar 2  is selected from the group consisting of phenyl, phenyl independently mono- or di-substituted with Y 2 , 5-10 membered heteroaryl and 5-10 membered heteroaryl mono- or di-substituted with Y 2 .  
 
     
     
         37 . The compound of  claim 35  wherein a is two, b is one and c is zero.  
     
     
         38 . The compound of  claim 35  wherein Ar 2  is selected from the group consisting of thienyl, 2,1,3-benzothiadiazolyl, imidazolyl, and 1,7-thiazopyrrolizinyl.  
     
     
         39 . The compound of  claim 35  selected from the group consisting of FG 1367, FG 1361, FG 1362, FG 1363, FG 1365, FG 1371, and FG 1473.  
     
     
         40 . The compound of  claim 35  having the structural formula:  
       
         
           
           
               
               
           
         
         or pharmaceutically acceptable salts thereof, wherein 
 wherein R 130 , R 131  and R 132  are each independently selected from the group consisting of —R′, —OR′, —OR″, —SR′, —SR″, —NR′R′, —NO 2 , —CN, -halogen, -trihalomethyl, trihalomethoxy, —C(O)R′, —C(O)OR′, —C(O)NR′R′, —C(O)NR′OR′, —C(NR′R′)═NOR′, —NR′—C(O)R′, —SO 2 R′, —SO 2 R″, —NR′—SO 2 —R′, —NR′—C(O)—NR′R′, tetrazol-5-yl, and —NR′—C(O)—OR′;  
 each R′ is independently selected from the group consisting of —H, (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl and (C 2 -C 8 ) alkynyl; and  
 
         R″ is selected from the group consisting of phenyl and phenyl independently mono-, di-substituted or tri-substituted with halogen or —CN, with the proviso that when a and b are each one then c is other than zero.  
       
     
     
         41 . The compound of  claim 40  selected from the group consisting of FG 1273, FG 1370, FG 1373, FG 1369, FG 1357, FG 1360, FG 1410, FG 1372, FG 1368, FG 1364, FG 1366, FG 1458, FG 1462, FG 1464, FG 1467, and FG 1470.  
     
     
         42 . The compound of  claim 1  wherein Ar 1  is benzodioxole and Ar 2  is thienyl or thienyl independently substituted with one or more Y 2 .  
     
     
         43 . The compound of  claim 42  having the structural formula:  
       
         
           
           
               
               
           
         
         or pharmaceutically acceptable salts thereof wherein R 124  is selected from the group consisting of —R′, —OR′, —OR″, —SR′, —SR″, —NR′R′, —NO 2 , —CN, -halogen, -trihalomethyl, trihalomethoxy, —C(O)R′, —C(O)OR′, —C(O)NR′R′, —C(O)NR′OR′, —C(NR′R′)═NOR′, —NR′—C(O)R′, —SO 2 R′, —SO 2 R″, —NR′—SO 2 ,—R′, —NR′—C(O)—NR′R′, tetrazol-5-yl, and —NR′—C(O)—OR′;  
         each R′ is independently selected from the group consisting of —H, (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl and (C 2 -C 8 ) alkynyl; and  
         each R″ is selected from the group consisting of phenyl and phenyl independently mono-, di-substituted or tri-substituted with halogen or —CN.  
       
     
     
         44 . The compound of  claim 43  wherein a is two, b is one and c is zero.  
     
     
         45 . The compound of  claim 43  selected from the group consisting of FG 1367, FG 1361, FG 1371 and FG 1473.  
     
     
         46 . A compound having an inhibitory effect on C-proteinase, said compound having the formula:  
       
         
           
           
               
               
           
         
         or pharmaceutically acceptable salts thereof, wherein: 
 g is an integer from 1 to 4;  
 h is an integer from 0 to 4;  
 i is an integer from 0 to 4;  
 Z is selected from the group consisting of (C 3 -C 10 ) cycloalkyl, (C 3 -C 10 ) cycloalkyl independently substituted with one or more Y 5 , 3-10 membered heterocycloalkyl, and 3-10 membered heterocycloalkyl independently substituted with one or more Y 5 ;  
 Ar 6  is selected from the group consisting of (C 5 -C 20 ) aryl, (C 5 -C 20 ) aryl independently substituted with one or more Y 6 , 5-20 membered heteroaryl, and 5-20 membered heteroaryl independently substituted with one or more Y 6 ;  
 each Y 5  is independently selected from the group consisting of a lipophilic functional group, (C 5 -C 20 ) aryl, (C 6 -C 26 ) alkaryl, 5-20 membered heteroaryl and 6-26 membered alk-heteroaryl;  
 each Y 6  is independently selected from the group consisting of —R′, —OR′, —OR″, —SR′, —SR″, —NR′R′, —NO 2 , —CN, -halogen, -trihalomethyl, trihalomethoxy, —C(O)R′, —C(O)OR′, —C(O)NR′R′, —C(O)NR′OR′, —C(NR′R′)═NOR′, —NR′—C(O)R′, —SO 2 R′, —SO 2 R″, —NR′—SO 2 —R′, —NR′—C(O)—NR′R′, tetrazol-5-yl, —NR′—C(O)—OR′, —C(NR′R′)═NR′, —S(O)—R′, —S(O)—R″, and —NR′—C(S)—NR′R′;  
 each R′ is independently selected from the group consisting of —H, (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl and (C 2 -C 8 ,) alkynyl; and  
 each R″ is independently selected from the group consisting of (C 5 -C 20 ) aryl and (C 5 -C 20 ) aryl independently substituted with one or more —OR′, —SR′, —NR′R′, —NO 2 , —CN, halogen or trihalomethyl groups,  
 with the proviso that when g and h are 1, i is 0, and Ar 6  is phenyl, then Z is other than C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkyl-lower alkyl, N-lower alkyl-piperazino-lower alkyl, (morpholino, thiomorpholino, piperidino, pyrrolidino, piperidyl or N-lower alkylpiperidyl)-lower alkyl.  
 
       
     
     
         47 . The compound of  claim 46  wherein g is two and i is zero.  
     
     
         48 . The compound of  claim 46  wherein: 
 Z is selected from the group consisting of adamantyl, cyclohexyl, morpholino, tetrahydrofuranyl, piperidyl, and piperidyl mono-substituted with Y 5 ;  
 Ar 6  is selected from the group consisting of phenyl and phenyl mono-substituted with Y 6 ; and  
 Y 5  is —(CH 2 ) n -phenyl, where n is an integer from 0 to 3.  
 
     
     
         49 . The compound of  claim 46  wherein Ar 6  is (C 1 -C 6 ) alkoxyphenyl.  
     
     
         50 . The compound of  claim 49  having the structural formula:  
       
         
           
           
               
               
           
         
         or pharmaceutically acceptable salts thereof.  
       
     
     
         51 . The compound of  claim 50  selected from the group consisting of FG 1131, FG 1306, FG 1335, FG 1379 and FG 1380.  
     
     
         52 . A compound having an inhibitory effect on C-proteinase, said compound having the structural formula:  
       
         
           
           
               
               
           
         
         or pharmaceutically acceptable salts thereof, wherein 
 r is an integer from 1 to 4;  
 s is an integer from 0 to 4;  
 Ar 11  is selected from the group consisting of (C 5 -C 20 ) aryl, (C 5 -C 20 ) aryl independently substituted with one or more Y 11  5-20 membered heteroaryl, and 5-20 membered heteroaryl independently substituted with one or more Y 11 ;  
 G is selected from the group consisting of:  
                     
 R 90  and R 91  are independently selected from the group consisting of hydrogen, (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, (C 3 -C 10 ) cycloalkyl, (C 5 -C 20 ) aryl, (C 5 -C 20 ) substituted aryl, (C 6 -C 26 ) alkaryl, (C 6 -C 26 ) substituted alkaryl, 5-20 membered heteroaryl, 5-20 membered substituted heteroaryl, 6-26 membered alk-heteroaryl, and 6-26 membered substituted alk-heteroaryl;  
 R 92  is independently selected from the group consisting of hydrogen, (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, and (C 2 -C 8 ) alkynyl; and  
 each Y 11 , R 93 , R 94 , R 95 , R 96 , R 97 , R 98 , R 99 , R 100 , R 101 , and R 102  is independently selected from the group consisting of an electron-donating functional group, an electron-withdrawing functional group, and a lipophilic functional group.  
 
       
     
     
         53 . The compound of  claim 52  wherein Ar 11  is selected from the group consisting of (C 5 -C 20 ) aryl and (C 5 -C 20 ) aryl independently substituted with one or more Y 11 .  
     
     
         54 . The compound of  claim 53  wherein each Y 11  is independently selected from the group consisting of -halogen, —R, —OR, —SR, —NRR, —NO, —NO 2 , —CN, -trihalomethyl, and —SO 2 NH 2 , where each R is independently selected from the group consisting of —H, (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl and (C 2 -C 8 ) alkynyl.  
     
     
         55 . The compound of  claim 52  having the structural formula:  
       
         
           
           
               
               
           
         
         or pharmaceutically acceptable salts thereof, wherein: 
 R 103 , R 104 , R 105 , R 106 , R 107  are each independently selected from the group consisting of hydrogen, halogen, —R, —OR, —SR, —NRR, —NO, —NO 2 , —CN, -trihalomethyl, —C(O)R, —C(O)OR, —C(O)NRR, —C(O)NRR, —C(NRR)═NOR, —C(O)NROR, —SO 2 NRR, and —NRSO 2 R; where each R is independently selected from the group consisting of H, (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, and (C 2 -C 8 ) alkynyl.  
 
       
     
     
         56 . The compound of  claim 52  which is selected from the group consisting of:  
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         57 . The compound of  claim 55  having the structural formula wherein r is 2, s is 2, and R 106  and R 107  are each hydrogen.  
     
     
         58 . The compound of  claim 52  wherein G has the structural formula:  
       
         
           
           
               
               
           
         
         and pharmaceutically acceptable salts, wherein: 
 R93, R 94 , R 95 , R 96 , R 97  and Y 11  are each independently selected from the group consisting of -halogen, —R, —OR, —SR, —NRR, —NO, —NO 2 , —CN, -trihalomethyl, and —SO 2 NH 2 ; where each R is independently selected from the group consisting of H, (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, and (C 2 -C 8 ) alkynyl.  
 
       
     
     
         59 . The compound of  claim 58  having the structural formula:  
       
         
           
           
               
               
           
         
         wherein: 
 R 111  and R 112  are hydrogen;  
 R 108 , R 109  and R 110  are each independently selected from the group consisting of —H, —R, —OR, —SR, —NRR, —NO 2 , —CN, halogen, trihalomethyl, —C(O)R, —C(O)OR, —C(O)NRR, —C(NRR)═NOR, —C(O)NROR, —SO 2 NRR, and —NRSO 2 R; and  
 each R is independently selected from the group consisting of H, (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl and (C 2 -C 8 ) alkynyl.  
 
       
     
     
         60 . The compound of  claim 59  wherein r and s are 2.  
     
     
         61 . The compound of  claim 60  having the structural formula:  
       
         
           
           
               
               
           
         
         or pharmaceutically acceptable salts thereof.  
       
     
     
         62 . The compound of  claim 52  wherein G has the structural formula:  
       
         
           
           
               
               
           
         
         and R 98 , R 99 , R 100 , R 101 , R 102  and Y 11  are each independently selected from the group consisting of -halogen, —R, —OR, —SR, —NRR, —NO, —NO 2 , —CN, -trihalomethyl, and —SO 2 NH 2 ; where each R is independently selected from the group consisting of —H, (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, and (C 2 -C 8 ) alkynyl.  
       
     
     
         63 . The compound of  claim 62  wherein Ar 11  is phenyl independently substituted with one or more Y 11 .  
     
     
         64 . The compound of  claim 63  wherein r and s are two, having the structural formula:  
       
         
           
           
               
               
           
         
         R 116  and R 117  are each hydrogen;  
         R 113 , R 114 , R 115  are each independently selected from the group consisting of —H, —R, —OR, —SR, —NRR, —NO 2 , —CN, halogen, trihalomethyl, —C(O)R, —C(O)OR, —C(O)NRR, —C(NRR)═NOR, —C(O)NROR, —SO 2 NRR, and —NRSO 2 R; and  
         each R is independently selected from the group consisting of (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl and (C 2 -C 8 ) alkynyl.  
       
     
     
         65 . The compound of  claim 64  having the structural formula:  
       
         
           
           
               
               
           
         
         or pharmaceutically acceptable salts thereof.  
       
     
     
         66 . A pharmaceutical composition comprising the compound of  claim 1 ,  46  or  52 , and a pharmaceutically acceptable carrier, diluent or excipient.  
     
     
         67 . A method of treating a disease related to inappropriate or unregulated production of collagen, said method comprising the step of administering to a subject in need thereof an effective amount of a compound according to  claim 1 ,  46  or  52 .  
     
     
         68 . The method of treating a fibrotic disorder selected from the group consisting of hepatic cirrhosis and arthritis, said method comprising the step of administering to a subject in need thereof an effective amount of a compound according to  claim 1 ,  46  or  52 .  
     
     
         69 . A zinc ion coordinating reagent, said reagent selected from the compounds of  claim 1 ,  46 , or  52 .  
     
     
         70 . The method of inhibiting an MMP, said method comprising the step of administering to a subject an effective amount of a compound according to  claim 1 ,  46 , or  52 .